Clearmind Medicine has filed a patent application with United States Patent and Trademark Office for the use of 3-methylmethcathinone, to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine CEO Issues Letter to Shareholders
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
- Clearmind Medicine announces international patent application on depression
- SciSparc says Clearmind submits international patent application for depression